Evidence map›Paper›PMID 42591605›Full record

ArticleFrontiers in artificial intelligence2026

DrugPred: an EdgeConv-GNN and Bio_ClinicalBERT based polypharmacy ADR prediction and specialist recommendation model.

J G Arjay, K Adit Pushan, N Roshanthraj, Brindha Subburaj, Sherly Alphonse, Girish Subramanian

Abstract read
In one paragraph

Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

J G ArjaySchool of Computer Science and Engineering, Vellore Institute of Technology, Chennai, India.
K Adit PushanSchool of Computer Science and Engineering, Vellore Institute of Technology, Chennai, India.
N RoshanthrajSchool of Computer Science and Engineering, Vellore Institute of Technology, Chennai, India.
Brindha SubburajSchool of Computer Science and Engineering, Vellore Institute of Technology, Chennai, India.
Sherly AlphonseSchool of Computer Science and Engineering, Vellore Institute of Technology, Chennai, India.
Girish SubramanianSchool of Business Administration, Penn State Harrisburg, Middletown, PA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adverse drug reactions (ADRs) are caused by medication and are considered a serious issue in healthcare when there is simultaneous use of different medications resulting in drug-drug interaction (DDI). Traditional approaches mostly focus on the effects caused by a single drug, and they fail to capture the side effects from drug combinations. In this research work, a deep learning-based DrugPred framework is proposed to predict ADR risks by integrating individual drug effects, interaction statistics of the drugs, and structural relationships between drug-interaction graphs. In the first phase, baseline association scores between individual drugs and their corresponding ADRs, such as nausea, liver toxicity, or cardiovascular effects, are learned using a multi-layer perceptron (MLP) trained on the OFFSIDES dataset, providing probabilistic values for individual drug-ADR pairs. In the second phase, a Graph Neural Network (GNN) based on the EdgeConv architecture is utilized to model drug-drug interactions using the TwoSIDES dataset, capturing relational dependencies by utilizing pairwise statistical values such as co-occurrence frequency and interaction statistics derived from pharmacovigilance signals, including transformed PRR-based signals. In the third phase, Bio_ClinicalBERT, which is a pre-trained transformer-based language model specifically trained on clinical notes and biomedical text, is used to encode drug pair representations and combine them with association and interaction scores through an attention-guided mechanism, which enables the model to adaptively weight heterogeneous features and finally performs multi-label ADR prediction. The proposed model achieves an accuracy of 95.73%, F1-score of 0.94, ROC-AUC of 0.993, and PR-AUC of 0.988. These results indicate that our proposed DrugPred framework is effective in the prediction of ADR risks with high precision and recall. Overall, the proposed framework provides a scalable approach for predicting ADRs in multi-drug settings. We further extend our framework with a retrieval-based guidance system that maps the risk levels of the predicted ADRs to appropriate System Organ Classes (SOC) and medical specialists to provide recommendations using real-world clinical data sources like PubMed and OpenFDA.

Indexed as

adverse drug reaction predictionclinical decision support systempharmacovigilancepolypharmacypublic health

Identifiers

PMID42591605
PMCPMC13462213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.